Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I
We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechani...
Gespeichert in:
Veröffentlicht in: | Endocrinology (Philadelphia) 2001-04, Vol.142 (4), p.1489 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 4 |
container_start_page | 1489 |
container_title | Endocrinology (Philadelphia) |
container_volume | 142 |
creator | Brink, M Price, S R Chrast, J Bailey, J L Anwar, A Mitch, W E Delafontaine, P |
description | We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechanisms and the involvement of the IGF-I system in these responses to ang II. Ang II infusion caused a significant decrease in body weight compared with that of pair-fed control rats. Kidney and left ventricular weights were significantly increased by ang II, whereas fat tissue was unchanged. Skeletal muscle mass was significantly decreased in the ang II-infused rats, and a reduction in lean muscle mass was a major reason for their overall loss of body weight. In skeletal muscles, ang II did not significantly decrease protein synthesis, but overall protein breakdown was accelerated; inhibiting lysosomal and calcium-activated proteases did not reduce the ang II-induced increase in muscle proteolysis. Circulating IGF-I levels were 33% lower in ang II rats vs. control rats, and this difference was reflected in lower IGF-I messenger RNA levels in the liver. Moreover, IGF-I, IGF-binding protein-3, and IGF-binding protein-5 messenger RNAs in the gastrocnemius were significantly reduced. To investigate whether the reduced circulating IGF-I accounts for the loss in muscle mass, we increased circulating IGF-I by coinfusing ang II and IGF-I, but this did not prevent muscle loss. Our data suggest that ang II causes a loss in skeletal muscle mass by enhancing protein degradation probably via its inhibitory effect on the autocrine IGF-I system. |
doi_str_mv | 10.1210/en.142.4.1489 |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_11250929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11250929</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-2ba38a1a2c21069cc71cf57e78843af61288e16a22c081d2ba1310bf824ee5a63</originalsourceid><addsrcrecordid>eNo1kM1OwzAQhH0A0VI4ckV-gZT4p4lzrCqgkSpxgXO1tTeJaepU_lHFQ_DOWAIuO1ppvlntEPLAyiXjrHxCt2SSL2Weqrki87Jkoqg5r2fkNoTPvEopxQ2ZMcZXZcObOfleu95OEV2wjrYttc4kjYGGI44YYaSnFPSI9AIhWtfTOPgp9QNFN4DTaOjZZzqzBnsPBqKdHAVnqJkurvDYpxFizoMUJ-2tw3whpNG6YrRHpL2fLnGgHeg4edrekesOxoD3f7ogHy_P75ttsXt7bTfrXaG5UrHgBxAKGHCdv64arWumu1WNtVJSQFex7EJWAee6VMxkOxOsPHSKS8QVVGJBHn9zz-lwQrM_e3sC_7X_70X8APYcZhc</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I</title><source>MEDLINE</source><source>Oxford Academic Journals (OUP)</source><source>EZB Electronic Journals Library</source><creator>Brink, M ; Price, S R ; Chrast, J ; Bailey, J L ; Anwar, A ; Mitch, W E ; Delafontaine, P</creator><creatorcontrib>Brink, M ; Price, S R ; Chrast, J ; Bailey, J L ; Anwar, A ; Mitch, W E ; Delafontaine, P</creatorcontrib><description>We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechanisms and the involvement of the IGF-I system in these responses to ang II. Ang II infusion caused a significant decrease in body weight compared with that of pair-fed control rats. Kidney and left ventricular weights were significantly increased by ang II, whereas fat tissue was unchanged. Skeletal muscle mass was significantly decreased in the ang II-infused rats, and a reduction in lean muscle mass was a major reason for their overall loss of body weight. In skeletal muscles, ang II did not significantly decrease protein synthesis, but overall protein breakdown was accelerated; inhibiting lysosomal and calcium-activated proteases did not reduce the ang II-induced increase in muscle proteolysis. Circulating IGF-I levels were 33% lower in ang II rats vs. control rats, and this difference was reflected in lower IGF-I messenger RNA levels in the liver. Moreover, IGF-I, IGF-binding protein-3, and IGF-binding protein-5 messenger RNAs in the gastrocnemius were significantly reduced. To investigate whether the reduced circulating IGF-I accounts for the loss in muscle mass, we increased circulating IGF-I by coinfusing ang II and IGF-I, but this did not prevent muscle loss. Our data suggest that ang II causes a loss in skeletal muscle mass by enhancing protein degradation probably via its inhibitory effect on the autocrine IGF-I system.</description><identifier>ISSN: 0013-7227</identifier><identifier>DOI: 10.1210/en.142.4.1489</identifier><identifier>PMID: 11250929</identifier><language>eng</language><publisher>United States</publisher><subject>Angiotensin II - pharmacology ; Animals ; Autocrine Communication - drug effects ; Blotting, Northern ; Blotting, Western ; Body Weight - drug effects ; Down-Regulation - drug effects ; Insulin-Like Growth Factor I - biosynthesis ; Insulin-Like Growth Factor I - genetics ; Insulin-Like Growth Factor I - pharmacology ; Liver - drug effects ; Liver - metabolism ; Male ; Muscle Proteins - biosynthesis ; Muscle Proteins - metabolism ; Muscle, Skeletal - drug effects ; Muscle, Skeletal - metabolism ; Muscle, Skeletal - pathology ; Nuclease Protection Assays ; Organ Size - drug effects ; Radioimmunoassay ; Rats ; Rats, Sprague-Dawley ; RNA, Messenger - biosynthesis ; Wasting Syndrome - chemically induced ; Wasting Syndrome - pathology</subject><ispartof>Endocrinology (Philadelphia), 2001-04, Vol.142 (4), p.1489</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c288t-2ba38a1a2c21069cc71cf57e78843af61288e16a22c081d2ba1310bf824ee5a63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11250929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brink, M</creatorcontrib><creatorcontrib>Price, S R</creatorcontrib><creatorcontrib>Chrast, J</creatorcontrib><creatorcontrib>Bailey, J L</creatorcontrib><creatorcontrib>Anwar, A</creatorcontrib><creatorcontrib>Mitch, W E</creatorcontrib><creatorcontrib>Delafontaine, P</creatorcontrib><title>Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I</title><title>Endocrinology (Philadelphia)</title><addtitle>Endocrinology</addtitle><description>We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechanisms and the involvement of the IGF-I system in these responses to ang II. Ang II infusion caused a significant decrease in body weight compared with that of pair-fed control rats. Kidney and left ventricular weights were significantly increased by ang II, whereas fat tissue was unchanged. Skeletal muscle mass was significantly decreased in the ang II-infused rats, and a reduction in lean muscle mass was a major reason for their overall loss of body weight. In skeletal muscles, ang II did not significantly decrease protein synthesis, but overall protein breakdown was accelerated; inhibiting lysosomal and calcium-activated proteases did not reduce the ang II-induced increase in muscle proteolysis. Circulating IGF-I levels were 33% lower in ang II rats vs. control rats, and this difference was reflected in lower IGF-I messenger RNA levels in the liver. Moreover, IGF-I, IGF-binding protein-3, and IGF-binding protein-5 messenger RNAs in the gastrocnemius were significantly reduced. To investigate whether the reduced circulating IGF-I accounts for the loss in muscle mass, we increased circulating IGF-I by coinfusing ang II and IGF-I, but this did not prevent muscle loss. Our data suggest that ang II causes a loss in skeletal muscle mass by enhancing protein degradation probably via its inhibitory effect on the autocrine IGF-I system.</description><subject>Angiotensin II - pharmacology</subject><subject>Animals</subject><subject>Autocrine Communication - drug effects</subject><subject>Blotting, Northern</subject><subject>Blotting, Western</subject><subject>Body Weight - drug effects</subject><subject>Down-Regulation - drug effects</subject><subject>Insulin-Like Growth Factor I - biosynthesis</subject><subject>Insulin-Like Growth Factor I - genetics</subject><subject>Insulin-Like Growth Factor I - pharmacology</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Male</subject><subject>Muscle Proteins - biosynthesis</subject><subject>Muscle Proteins - metabolism</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Muscle, Skeletal - metabolism</subject><subject>Muscle, Skeletal - pathology</subject><subject>Nuclease Protection Assays</subject><subject>Organ Size - drug effects</subject><subject>Radioimmunoassay</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>RNA, Messenger - biosynthesis</subject><subject>Wasting Syndrome - chemically induced</subject><subject>Wasting Syndrome - pathology</subject><issn>0013-7227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1OwzAQhH0A0VI4ckV-gZT4p4lzrCqgkSpxgXO1tTeJaepU_lHFQ_DOWAIuO1ppvlntEPLAyiXjrHxCt2SSL2Weqrki87Jkoqg5r2fkNoTPvEopxQ2ZMcZXZcObOfleu95OEV2wjrYttc4kjYGGI44YYaSnFPSI9AIhWtfTOPgp9QNFN4DTaOjZZzqzBnsPBqKdHAVnqJkurvDYpxFizoMUJ-2tw3whpNG6YrRHpL2fLnGgHeg4edrekesOxoD3f7ogHy_P75ttsXt7bTfrXaG5UrHgBxAKGHCdv64arWumu1WNtVJSQFex7EJWAee6VMxkOxOsPHSKS8QVVGJBHn9zz-lwQrM_e3sC_7X_70X8APYcZhc</recordid><startdate>200104</startdate><enddate>200104</enddate><creator>Brink, M</creator><creator>Price, S R</creator><creator>Chrast, J</creator><creator>Bailey, J L</creator><creator>Anwar, A</creator><creator>Mitch, W E</creator><creator>Delafontaine, P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200104</creationdate><title>Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I</title><author>Brink, M ; Price, S R ; Chrast, J ; Bailey, J L ; Anwar, A ; Mitch, W E ; Delafontaine, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-2ba38a1a2c21069cc71cf57e78843af61288e16a22c081d2ba1310bf824ee5a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Angiotensin II - pharmacology</topic><topic>Animals</topic><topic>Autocrine Communication - drug effects</topic><topic>Blotting, Northern</topic><topic>Blotting, Western</topic><topic>Body Weight - drug effects</topic><topic>Down-Regulation - drug effects</topic><topic>Insulin-Like Growth Factor I - biosynthesis</topic><topic>Insulin-Like Growth Factor I - genetics</topic><topic>Insulin-Like Growth Factor I - pharmacology</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Male</topic><topic>Muscle Proteins - biosynthesis</topic><topic>Muscle Proteins - metabolism</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Muscle, Skeletal - metabolism</topic><topic>Muscle, Skeletal - pathology</topic><topic>Nuclease Protection Assays</topic><topic>Organ Size - drug effects</topic><topic>Radioimmunoassay</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>RNA, Messenger - biosynthesis</topic><topic>Wasting Syndrome - chemically induced</topic><topic>Wasting Syndrome - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brink, M</creatorcontrib><creatorcontrib>Price, S R</creatorcontrib><creatorcontrib>Chrast, J</creatorcontrib><creatorcontrib>Bailey, J L</creatorcontrib><creatorcontrib>Anwar, A</creatorcontrib><creatorcontrib>Mitch, W E</creatorcontrib><creatorcontrib>Delafontaine, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Endocrinology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brink, M</au><au>Price, S R</au><au>Chrast, J</au><au>Bailey, J L</au><au>Anwar, A</au><au>Mitch, W E</au><au>Delafontaine, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I</atitle><jtitle>Endocrinology (Philadelphia)</jtitle><addtitle>Endocrinology</addtitle><date>2001-04</date><risdate>2001</risdate><volume>142</volume><issue>4</issue><spage>1489</spage><pages>1489-</pages><issn>0013-7227</issn><abstract>We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechanisms and the involvement of the IGF-I system in these responses to ang II. Ang II infusion caused a significant decrease in body weight compared with that of pair-fed control rats. Kidney and left ventricular weights were significantly increased by ang II, whereas fat tissue was unchanged. Skeletal muscle mass was significantly decreased in the ang II-infused rats, and a reduction in lean muscle mass was a major reason for their overall loss of body weight. In skeletal muscles, ang II did not significantly decrease protein synthesis, but overall protein breakdown was accelerated; inhibiting lysosomal and calcium-activated proteases did not reduce the ang II-induced increase in muscle proteolysis. Circulating IGF-I levels were 33% lower in ang II rats vs. control rats, and this difference was reflected in lower IGF-I messenger RNA levels in the liver. Moreover, IGF-I, IGF-binding protein-3, and IGF-binding protein-5 messenger RNAs in the gastrocnemius were significantly reduced. To investigate whether the reduced circulating IGF-I accounts for the loss in muscle mass, we increased circulating IGF-I by coinfusing ang II and IGF-I, but this did not prevent muscle loss. Our data suggest that ang II causes a loss in skeletal muscle mass by enhancing protein degradation probably via its inhibitory effect on the autocrine IGF-I system.</abstract><cop>United States</cop><pmid>11250929</pmid><doi>10.1210/en.142.4.1489</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0013-7227 |
ispartof | Endocrinology (Philadelphia), 2001-04, Vol.142 (4), p.1489 |
issn | 0013-7227 |
language | eng |
recordid | cdi_pubmed_primary_11250929 |
source | MEDLINE; Oxford Academic Journals (OUP); EZB Electronic Journals Library |
subjects | Angiotensin II - pharmacology Animals Autocrine Communication - drug effects Blotting, Northern Blotting, Western Body Weight - drug effects Down-Regulation - drug effects Insulin-Like Growth Factor I - biosynthesis Insulin-Like Growth Factor I - genetics Insulin-Like Growth Factor I - pharmacology Liver - drug effects Liver - metabolism Male Muscle Proteins - biosynthesis Muscle Proteins - metabolism Muscle, Skeletal - drug effects Muscle, Skeletal - metabolism Muscle, Skeletal - pathology Nuclease Protection Assays Organ Size - drug effects Radioimmunoassay Rats Rats, Sprague-Dawley RNA, Messenger - biosynthesis Wasting Syndrome - chemically induced Wasting Syndrome - pathology |
title | Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T15%3A51%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin%20II%20induces%20skeletal%20muscle%20wasting%20through%20enhanced%20protein%20degradation%20and%20down-regulates%20autocrine%20insulin-like%20growth%20factor%20I&rft.jtitle=Endocrinology%20(Philadelphia)&rft.au=Brink,%20M&rft.date=2001-04&rft.volume=142&rft.issue=4&rft.spage=1489&rft.pages=1489-&rft.issn=0013-7227&rft_id=info:doi/10.1210/en.142.4.1489&rft_dat=%3Cpubmed%3E11250929%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11250929&rfr_iscdi=true |